Here we aim to proviede an up-to-date directory of current and past optogenetic trials. Please e-mail us if you find a trial or results missing:
| ID | Phase | Actuator | Vector | Target Cells | Sponsor | Condition | Results |
|---|---|---|---|---|---|---|---|
| NCT02556736 | I/IIa | ChR2 | AAV2 2.7m8 | RGC | AbbVie/RetroSense | RP | Conference report (Bunnell, Yuan, Lopez, 2025) and Trial results data reported on clincialtrials.gov |
| NCT03326336 (PIONEER) | I/IIa | ChrimsonR | AAV2 7m8 | RGC | GenSight Biologic | RP | Case report: Object localization in near spase, EEG ( Sahel et al., 2021) |
| ChiCTR2200062174 (UGX-201) | I | mGluR4 -MW-Opsin chimera under synuclein gamma promoter | AAV2 7m8 | RGC | Ugenex Therapeutics | RP | Conference report: VA improvement (Luo et al., 2025); Phase 1 Results: VA improvement observed only in treated eye and at biologically plausible time scale. FST improvement similar in treated and untreated eye (Han X et al. AJO, 2026) |
| NCT04278131 | I/II | ChronosFP | AAV2 | RGC | Bionic Sight | RP | Press release: Increase in light sensitivity and VA ( Bionic Sight, 2025 ) |
| NCT04919473, NCT05921162 | I/II + Follow-Up | MCO-1 / vMCO-010 | AAV2 | BC | Nanoscope Therapeutics | RP, ABCA4-associated | Case Series: Improvement in VA, visual field and Quality of Life, no controls included (Mohanty et al., 2025 ) |
| NCT04945772 (RESTORE), NCT06162585 (REMAIN) | I/II + Follow-Up | MCO-010 | AAV2 | BC | Nanoscope Therapeutics | RP | Press release: Significant improvement in VA ( FirstWord, 2025; Nanoscope Therapeutics, 2024 ) Conference report: No SAE ( Boyer et al., 2023) and functional gain prevailing after 3 years ( Mahajan V et al., 2026) |
| NCT05417126 (STARLIGHT), NCT06048185 | II + Follow-Up | vMCO-010 | AAV2 | BC | Nanoscope Therapeutics | M. Stargardt | Case Series: Improvement in VA, visual field and Quality of Life, no controls included (Lam et al., 2025) |
| NCT06292650, NCT07282457 | I | PsCatCh2.0 | AAV? | RGC | Zhongmou Therapeutics | RP | Conference report: VA improvement (Zhou W et al., 2025) and clinically meaningful VA improvement in 83.3% (5/6), equalling mean -0.61 logMAR from 2.42logMAR at baseline. Accliamed improvement in hue discrimination. No improvement in two sham injected patients (Zhou W et al., 2026)) |
| NCT06460844 (ENVISION) | I | ChRown | ARMMs | RGC | Ray Therapeutics | RP, Choroideremia | |
| NCT07311863 | I | Ugenex Therapeutics | RP |